Jazz Pharmaceuticals plc - Ordinary Shares (JAZZ) stock analysis

JAZZ · Jazz Pharmaceuticals plc - Ordinary Shares

Latest recorded price: USD 239.77

Model-estimated fair value: USD 188.49. This assumption-based estimate is for general research and is not investment advice.

Sector and industry: Healthcare · Biotechnology

At $239.77, JAZZ trades 27.2% above the model's base-case value of $188.49. Using Operating FCFF DCF (revenue x margin - reinvestment), the model estimates $140.35 in the conservative case and $244.72 in the optimistic case, with a valuation confidence score of 55/100. About 76% of the value comes from the terminal value, so the result is sensitive to long-term growth and discount-rate assumptions. Fiscal 2025 figures: revenue growth 5.3%, free cash flow margin 30.4%, ROIC -4.8%. The model flags 1 risk signal for this company.

Similar companies in Healthcare